• 1
    Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 2343.
  • 2
    Janz M, Harbeck N, Dettmar P et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002; 97: 27882.
  • 3
    Swamynathan SK, Nambiar A, Guntaka RV. Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes. FASEB J 1998; 12: 51522.
  • 4
    Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 2001; 20: 382130.
  • 5
    Ashizuka M, Fukuda T, Nakamura T et al. Novel translational control through an iron-responsive element by interaction of multifunctional protein YB-1 and IRP2. Mol Cell Biol 2002; 22: 637583.
  • 6
    Evdokimova V, Ruzanov P, Anglesio MS et al. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol 2006; 26: 27792.
  • 7
    Ohga T, Uchiumi T, Makino Y et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998; 273: 59976000.
  • 8
    Bargou RC, Jurchott K, Wagener C et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 44750.
  • 9
    Rubinstein DB, Stortchevoi A, Boosalis M, Ashfaq R, Guillaume T. Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res 2002; 62: 498591.
  • 10
    Yahata H, Kobayashi H, Kamura T et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002; 128: 6216.
  • 11
    Oda Y, Ohishi Y, Saito T et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003; 199: 2518.
  • 12
    Koike K, Uchiumi T, Ohga T et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997; 417: 3904.
  • 13
    Hayakawa H, Uchiumi T, Fukuda T et al. Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 2002; 41: 12.
  • 14
    Ise T, Nagatani G, Imamura T et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59: 3426.
  • 15
    Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities, and binds several DNA repair proteins. Nucleic Acids Res 2004; 32: 31627.
  • 16
    Izumi H, Imamura T, Nagatani G et al. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′[RIGHTWARDS ARROW]5′ exonuclease activity. Nucleic Acids Res 2001; 29: 12007.
  • 17
    Marenstein DR, Ocampo MT, Chan MK et al. Stimulation of human endonuclease III by Y box-binding protein 1 (DNA-binding protein B). Interaction between a base excision repair enzyme and a transcription factor. J Biol Chem 2001; 276: 21.
  • 18
    Guay D, Garand C, Reddy S, Schmutte C, Lebel M. The human NTH1 enzyme is a relevant target to potentiate cisplatin cytotoxicity in YB-1 overexpressing tumor cells. Cancer Sci 2008; 99: 7629.
  • 19
    Di Cresce C, Koropatnick J. Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets 2010; 10: 55565.
  • 20
    de Souza-Pinto NC, Mason PA, Hashiguchi K et al. Novel DNA mismatch-repair activity involving YB-1 in human mitochondria. DNA Repair 2009; 8: 70419.
  • 21
    Rhodes DR, Yu J, Shanker K et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 16.
  • 22
    Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol 2005; 26: 60713.
  • 23
    Habibi G, Leung S, Law JH et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008; 10: R86.
  • 24
    Dahl E, En-Nia A, Wiesmann F et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009; 9: 410.
  • 25
    Gluz O, Mengele K, Schmitt M et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 2009; 27: 614451.
  • 26
    Fujita T, Ito K, Izumi H et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005; 11: 883744.
  • 27
    To K, Fotovati A, Reipas KM et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70: 284051.
  • 28
    Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer 2010; 10: 388.
  • 29
    Guay D, Evoy AA, Paquet E et al. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol 2008; 40: 2492507.
  • 30
    Davydova EK, Evdokimova VM, Ovchinnikov LP, Hershey JW. Overexpression in COS cells of p50, the major core protein associated with mRNA, results in translation inhibition. Nucleic Acids Res 1997; 25: 29116.
  • 31
    Evdokimova V, Tognon C, Ng T et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial–mesenchymal transition. Cancer Cell 2009; 15: 40215.
  • 32
    Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8: 29016.
  • 33
    LaRue KE, Khalil M, Freyer JP. Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors. Cancer Res 2004; 64: 162131.
  • 34
    Xing H, Wang S, Hu K et al. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J Cancer Res Clin Oncol 2005; 131: 5119.
  • 35
    Watanabe M, Furuno N, Goebl M et al. Molecular cloning of the human gene, CCG2, that complements the BHK-derived temperature-sensitive cell cycle mutant tsBN63: identity of CCG2 with the human X chromosomal SCAR/RPS4X gene. J Cell Sci 1991; 100: 3543.